**米氮平（）**，商品名为**樂活憂（港台）/瑞美隆（中国大陆）（Remeron）**\[1\]，是一种[去甲肾上腺素和特异性5-羟色胺能抗抑郁药](../Page/去甲肾上腺素和特异性5-羟色胺能抗抑郁药.md "wikilink")
([NaSSA](../Page/去甲肾上腺素和特异性5-羟色胺能抗抑郁药.md "wikilink")) \[2\]
，主要用来治疗[抑郁症](../Page/抑郁症.md "wikilink")。米氮平也经常被用作[抗焦虑药](../Page/抗焦虑药.md "wikilink")、[安眠药](../Page/安眠药.md "wikilink")、[止吐药和](../Page/止吐药.md "wikilink")[食欲促进剂](../Page/食欲促进剂.md "wikilink")。若按[分子结构分类](../Page/分子结构.md "wikilink")，米氮平被分类为[四环类抗抑郁药](../Page/四环类抗抑郁药.md "wikilink")(TeCA)
，并且为[米安舍林的](../Page/米安舍林.md "wikilink")6-[氮杂类似物](../Page/氮杂.md "wikilink")。\[3\]
米氮平也是一种[外消旋混合物](../Page/外消旋混合物.md "wikilink")，包含(*R*)- 和
(*S*)-[异构体](../Page/异构体.md "wikilink")。\[4\]

## 医疗用途

### 已批准的和适应症外使用

米氮平主要用来治疗[重度抑郁症和其他精神障碍](../Page/重度抑郁症.md "wikilink")。\[5\]\[6\]

然而研究发现，米氮平对以下症状也有一定疗效，所以米氮平有时候也会被以[适应症外使用的形式处方给以下症状的治疗](../Page/适应症外使用.md "wikilink"):

  - [广泛性焦虑症](../Page/广泛性焦虑症.md "wikilink")\[7\]\[8\]
  - [社交恐惧症](../Page/社交恐惧症.md "wikilink")\[9\]\[10\]
  - [强迫症](../Page/强迫症.md "wikilink")\[11\]\[12\]
  - [恐慌症](../Page/恐慌症.md "wikilink")\[13\]\[14\]\[15\]
  - [创伤后应激障碍](../Page/创伤后应激障碍.md "wikilink")\[16\]
  - [食欲不振](../Page/食欲不振.md "wikilink")/[体重过低](../Page/体重过低.md "wikilink")\[17\]\[18\]\[19\]
  - [失眠](../Page/失眠.md "wikilink")\[20\]\[21\]
  - [恶心](../Page/恶心.md "wikilink")/[呕吐](../Page/呕吐.md "wikilink")\[22\]\[23\]\[24\]
  - [瘙痒](../Page/瘙痒.md "wikilink")\[25\]\[26\]
  - [头痛和](../Page/头痛.md "wikilink")[偏头痛](../Page/偏头痛.md "wikilink")\[27\]\[28\]\[29\]

### 研究性的

有过文献报道的使用米氮平进行过实验性治疗的症状包括:

  - [睡眠呼吸暂停](../Page/睡眠呼吸暂停.md "wikilink")/[低呼吸量](../Page/低呼吸量.md "wikilink")\[30\]\[31\]
  - 不适当的[性行为和其他由](../Page/性行为.md "wikilink")[自闭症和其他广泛性发育障碍等导致的继发症状](../Page/自闭症.md "wikilink")。\[32\]\[33\]\[34\]\[35\]
  - [抗精神病药导致的](../Page/抗精神病药.md "wikilink")[静坐不能](../Page/静坐不能.md "wikilink")\[36\]\[37\]
  - [药物戒断](../Page/药物戒断.md "wikilink")、[药物依赖和](../Page/药物依赖.md "wikilink")[戒毒](../Page/戒毒.md "wikilink")\[38\]
  - [精神分裂症导致的消极](../Page/精神分裂症.md "wikilink")、抑郁和认知障碍。（作为辅助治疗）\[39\]\[40\]
  - 有文献报道，一例伴有视觉幻觉的[帕金森氏病精神病患者在使用米氮平后症状有所减轻](../Page/帕金森氏病.md "wikilink")。\[41\]
    这与近期发现的作用于[5-HT<sub>2A</sub>受体的](../Page/5-HT2A受体.md "wikilink")[反激动剂可以有效地减轻帕金森氏病的精神病症状这个事实相吻合](../Page/反激动剂.md "wikilink")。\[42\]

### 有效性和耐受性

2010年，NICE发布了治疗抑郁症的指南，其中包括对抗抑郁药的综述。它建议将通用[SSRIs作为第一线选择](../Page/选择性5-羟色胺再摄取抑制剂.md "wikilink")，因为它们“与其他抗抑郁药同样有效并且具有有利的风险-效益比”。\[43\]关于米氮平，它发现：“米氮平与其他抗抑郁药在任何疗效指标上没有差异，尽管在达到缓解方面，米氮平似乎具有统计学但不具有临床意义的优势。此外，米氮平具有优于[SSRIs的统计学优势](../Page/选择性5-羟色胺再摄取抑制剂.md "wikilink")。就减少抑郁症状而言，这种差异在临床上并不重要。然而，有强有力的证据表明服用米氮平的患者由于副作用而不太可能提早离开治疗，尽管对于报告副作用的患者不是这种情况或因任何原因提早离开治疗。“\[44\]\]

2011年Cochrane评价将米氮平与其他抗抑郁药进行了比较，结果发现，虽然它对患者的起效较快（在第2周时），但在第6周时它与其他的抗抑郁药大致相同。\[45\]

一项针对抗抑郁药和睡眠的2012年评论发现，在许多因抑郁引起[睡眠障碍的患者中](../Page/睡眠障碍.md "wikilink")，米氮平减少了入睡所需的时间并提高了睡眠质量，但在某些人中，它会扰乱睡眠，有8％至28％的人会有[不安腿综合征](../Page/不寧腿綜合症.md "wikilink")，并且它在极少数情况下导致[REM睡眠行为障碍](../Page/快速動眼期.md "wikilink")。

2018年有项系统评价和网络荟萃分析比较了12种抗抑郁药物的疗效和耐受性，结果显示米氮平是头对头研究中最有效的抗抑郁药之一。\[46\]

在第1周之后，相较于SSRI，米氮平有着更快的起效时间。\[47\]\[48\]

## 副作用

2011年Cochrane评价发现，与其他抗抑郁药相比，它更容易引起体重增加和[嗜睡](../Page/嗜睡症.md "wikilink")，但它比[三环类抗抑郁药引起震颤的可能性更小](../Page/三环类抗抑郁药.md "wikilink")，并且比SSRIs更不可能引起恶心和性功能障碍。\[49\]

米氮平不被认为存在很多副作用的风险，这些副作用通常和其他抗抑郁药，例如SSRI，有关，并且当他们一起使用时可以改善某些副作用。这些不良反应包括[食欲减退](../Page/食欲不振.md "wikilink")，体重减轻，[失眠](../Page/失眠.md "wikilink")，[恶心和](../Page/恶心.md "wikilink")[呕吐](../Page/呕吐.md "wikilink")，[腹泻](../Page/腹瀉.md "wikilink")，[尿潴留](../Page/尿瀦留.md "wikilink")，[体温升高](../Page/体温过高.md "wikilink")，出汗过多，瞳孔扩张和[性功能障碍](../Page/性功能障碍.md "wikilink")。\[50\]\[51\]

一般地，有些抗抑郁药，例如SSRI，会自相矛盾地加剧一些人的抑郁或焦虑或自杀意念。\[52\]尽管米氮平具有镇静作用，但据信也有能力做到这一点，所以在美国和其他一些国家，它带有黑框标签来警告这些潜在的影响。

2000年发表的一份病例报告指出，米氮平可以抵消[可乐定的作用](../Page/可乐定.md "wikilink")，导致血压升高。\[53\]

### 不良反应发生率\[54\]

非常常见（≥1/10）

  - 体重增加
  - 食欲增加
  - 嗜睡
  - 镇静作用
  - [口干](../Page/口乾.md "wikilink")

常见（≥1/100\~＜1/10）

  - 梦异常
  - 意思混乱
  - [焦虑](../Page/焦虑症.md "wikilink")
  - 失眠

不常见（≥1,000\~\<1/100）

  - [梦魇](../Page/梦魇.md "wikilink")
  - [躁狂症](../Page/躁狂症.md "wikilink")
  - [兴奋](../Page/兴奋.md "wikilink")
  - [幻觉](../Page/幻觉.md "wikilink")
  - 精神运动性坐立不安（包括[静坐不能](../Page/静坐不能.md "wikilink")、运动机能亢进）
  - 感觉异常
  - [不宁腿症状](../Page/不寧腿綜合症.md "wikilink")
  - [低血压](../Page/低血壓.md "wikilink")
  - 口腔感觉减退

罕见（≥1/10,000\~\>1/1,000）

  - 肌痉挛
  - 血清氨基转移酶增加

频率不详

  - [骨髓抑制](../Page/骨髓抑制.md "wikilink")（[粒细胞减少](../Page/粒细胞.md "wikilink")、粒细胞缺乏、再生性贫血以及[血小板减少症](../Page/血小板.md "wikilink")）
  - [嗜酸性粒细胞增多](../Page/嗜酸性粒细胞增多症.md "wikilink")
  - [低钠血症](../Page/低血鈉症.md "wikilink")
  - 自杀意图
  - 自杀行为
  - [惊厥](../Page/驚厥.md "wikilink")（发作）
  - [5-羟色胺综合征](../Page/血清素综合症.md "wikilink")
  - 口腔感觉异常
  - 口唇[水肿](../Page/水肿.md "wikilink")
  - [Stevens-Johnson综合征](../Page/史蒂芬斯－強森症候群.md "wikilink")
  - 大疱性皮炎
  - 多形性红斑
  - 中毒性表皮坏死

### 停药

米氮平和其他抗抑郁药可能在停止服用后引发停药综合征。\[55\]\[56\]\[57\]建议逐渐缓慢减少剂量，以尽量减少停药综合征。\[58\]突然停止米氮平治疗的后果可能包括抑郁，[焦虑](../Page/焦虑症.md "wikilink")，[耳鸣](../Page/耳鸣.md "wikilink")，[惊恐发作](../Page/惊恐发作.md "wikilink")，[眩晕](../Page/眩暈_\(醫學\).md "wikilink")，精神运动激动，[易怒](../Page/易怒.md "wikilink")，[食欲减退](../Page/食欲减退.md "wikilink")，[失眠](../Page/失眠.md "wikilink")，[腹泻](../Page/腹泻.md "wikilink")，[恶心](../Page/恶心.md "wikilink")，[呕吐](../Page/呕吐.md "wikilink")，[流感类似](../Page/流感.md "wikilink")[过敏和](../Page/过敏.md "wikilink")[瘙痒症](../Page/瘙痒症.md "wikilink")，[头痛](../Page/头痛.md "wikilink")，有时会有[轻度躁狂或](../Page/轻度狂躁.md "wikilink")[躁狂症](../Page/躁狂症.md "wikilink")。\[59\]\[60\]\[61\]\[62\]\[63\]

## 药物相互作用

与细胞色素（[CYP](../Page/细胞色素P450.md "wikilink")）[P450同工酶](../Page/细胞色素P450.md "wikilink")[CYP1A2](../Page/CYP1A2.md "wikilink")，[CYP2D6和](../Page/CYP2D6.md "wikilink")/或[CYP3A4的抑制剂或诱导剂同时使用可导致米氮平的浓度改变](../Page/CYP3A4.md "wikilink")，因为这些是负责其代谢的主要酶。\[64\]\[65\]例如，已知[氟西汀和](../Page/氟西汀.md "wikilink")[帕罗西汀](../Page/帕罗西汀.md "wikilink")（这些酶的抑制剂）适度增加米氮平水平，而[卡马西平](../Page/卡马西平.md "wikilink")（一种诱导剂）可显著降低米氮平水平。\[66\]据报道，在肝功能损害和中度肾功能损害的人群中，米氮平口服清除率降低约30％；而严重肾功能损害患者的口服清除率减少50％。\[67\]

根据制造商提供的信息，米氮平不应在任何[单胺氧化酶抑制剂](../Page/单胺氧化酶抑制剂.md "wikilink")（[MAOI](../Page/单胺氧化酶抑制剂.md "wikilink")）停用后两周内开始使用；同样，MAOI不应在停用米氮平后两周内给药。\[68\]米氮平与[SSRI](../Page/选择性5-羟色胺再摄取抑制剂.md "wikilink")，[SNRI或](../Page/5-羟色胺和去甲肾上腺素再摄取抑制剂.md "wikilink")[TCA联合作为增强策略被认为是相对安全的](../Page/三环类抗抑郁药.md "wikilink")，而且通常用于治疗。\[69\][文拉法辛和米氮平的组合](../Page/文拉法辛.md "wikilink")，有时被称为“加州火箭燃料”。\[70\]\[71\]已知在氟西汀和米氮平同时给药的情况下可能发生[5-羟色胺综合征](../Page/血清素综合症.md "wikilink")。

## 过量

如果服用过量，米氮平被认为是相对安全的\[72\]，尽管过量服用的毒性比大多数SSRIs（[西酞普兰除外](../Page/西酞普兰.md "wikilink")）略高。\[73\]与三环类抗抑郁药不同，米氮平在最大推荐剂量的7至22倍时未显示出明显的心血管不良反应。\[74\]与三环类抗抑郁药相比，过量服用标准剂量30至50倍的病例报告称药物相对无毒。\[75\]\[76\]

据报道，有12人死于米氮平过量。\[77\]\[78\]米氮平的致命毒性指数（每百万处方死亡人数）为3.1（95％CI：0.1至17.2）。这类似于用SSRIs观察到的情况。\[79\]

## 药理学

### 药效学

| Ki(nm)                                                 | 物种            | 来源 | 参考                           |
| ------------------------------------------------------ | ------------- | -- | ---------------------------- |
| [SERT](../Page/血清素轉運體.md "wikilink")                   | \>10,000      | 人类 | \[81\]\[82\]                 |
| [NET](../Page/去甲腎上腺素轉運體.md "wikilink")                 | ≥4,600        | 人类 | \[83\]\[84\]                 |
| [DAT](../Page/多巴胺转运体.md "wikilink")                    | \>10,000      | 人类 | \[85\]\[86\]                 |
| [5-HT<sub>1A</sub>](../Page/5-HT1A.md "wikilink")      | 3,330\~5,010  | 人类 | \[87\]\[88\]                 |
| [5-HT<sub>1B</sub>](../Page/5-HT1B.md "wikilink")      | 3,534\~12,600 | 人类 | \[89\]\[90\]                 |
| [5-HT<sub>1D</sub>](../Page/5-HT1D.md "wikilink")      | 794-5,010     | 人类 | \[91\]\[92\]                 |
| [5-HT<sub>1E</sub>](../Page/5-HT1E.md "wikilink")      | 728           | 人类 | \[93\]                       |
| [5-HT<sub>1F</sub>](../Page/5-HT1F.md "wikilink")      | 583           | 人类 | \[94\]                       |
| [**5-HT<sub>2A</sub>**](../Page/5-HT2受體.md "wikilink") | **6.3\~69**   | 人类 | \[95\]\[96\]\[97\]           |
| [5-HT<sub>2B</sub>](../Page/5-HT2B受體.md "wikilink")    | 200           | 人类 | \[98\]                       |
| [**5-HT<sub>2C</sub>**](../Page/5-HT2受體.md "wikilink") | **8.9\~39**   | 人类 | \[99\]\[100\]\[101\]         |
| **[5-HT<sub>3</sub>](../Page/5-HT3.md "wikilink")**    | **7.9**       | 人类 | \[102\]                      |
| [5-HT<sub>4L</sub>](../Page/5-HT4受體.md "wikilink")     | \>10,000      | 人类 | \[103\]                      |
| [5-HT<sub>5A</sub>](../Page/5-HT5A.md "wikilink")      | 670           | 人类 | \[104\]                      |
| [5-HT<sub>6</sub>](../Page/5-HT6.md "wikilink")        | ND            | ND | ND                           |
| [5-HT<sub>7</sub>](../Page/5-HT7.md "wikilink")        | 265           | 人类 | \[105\]\[106\]               |
| [α<sub>1A</sub>](../Page/Α1A.md "wikilink")            | 316\~1,815    | 人类 | \[107\]                      |
| [**α<sub>2A</sub>**](../Page/Α2A.md "wikilink")        | **20**        | 人类 | \[108\]\[109\]               |
| [**α<sub>2B</sub>**](../Page/Α2B.md "wikilink")        | **88**        | 人类 | \[110\]                      |
| [**α<sub>2C</sub>**](../Page/Α2C.md "wikilink")        | **18**        | 人类 | \[111\]\[112\]               |
| [β](../Page/Β受体.md "wikilink")                         | \>10,000      | 人类 | \[113\]                      |
| [D<sub>1</sub>](../Page/多巴胺受体D1.md "wikilink")         | \~4167        | 大鼠 | \[114\]                      |
| [D<sub>2</sub>](../Page/多巴胺受體D2.md "wikilink")         | \>5,454       | 人类 | \[115\]\[116\]               |
| [D<sub>3</sub>](../Page/多巴胺受体D3.md "wikilink")         | 5723          | 人类 | \[117\]\[118\]               |
| [D<sub>4</sub>](../Page/多巴胺受体D4.md "wikilink")         | 2,518         | 人类 | \[119\]                      |
| [**H<sub>1</sub>**](../Page/H1受体.md "wikilink")        | **0.14\~1.6** | 人类 | \[120\]\[121\]\[122\]\[123\] |
| [H<sub>2</sub>](../Page/H2受体.md "wikilink")            | \>10,000      | 大鼠 | \[124\]\[125\]               |
| [H<sub>3</sub>](../Page/H3受体.md "wikilink")            | 83,200        | 人类 | \[126\]                      |
| [H<sub>4</sub>](../Page/H4受体.md "wikilink")            | \>100,000     | 人类 | \[127\]                      |
| [mAch](../Page/蕈毒鹼型乙醯膽鹼受體.md "wikilink")               | 670           | 人类 | \[128\]\[129\]               |
| [VGSC](../Page/鈉離子通道.md "wikilink")                    | 6,905         | 大鼠 | \[130\]                      |
| [VDCC](../Page/钙离子通道.md "wikilink")                    | \>10,000      | 大鼠 | \[131\]                      |

米氮平\[80\]

米氮平有时被分类为去甲肾上腺素和特异性五羟色胺能能抗抑郁药（NaSSA），\[132\]尽管支持此分类的证据并不可靠。\[133\]米氮平有抗去甲肾上腺素、[组胺和](../Page/组胺.md "wikilink")5-羟色胺受体的功效。\[134\]\[135\]它特别是肾上腺素α
<sub>2A</sub>
，α<sub>2B</sub>，和α<sub>2C</sub>受体、组胺H<sub>1</sub>受体和5-羟色胺5-HT<sub>2A</sub>、5-HT<sub>2C</sub>和5-HT<sub>3</sub>的[拮抗剂或](../Page/受体拮抗剂.md "wikilink")[反向激动剂](../Page/反激动剂.md "wikilink")。\[136\]\[137\]不同于许多其他的抗抑郁药，它不抑制5-羟色胺、去甲肾上腺素或[多巴胺的再摄取](../Page/多巴胺.md "wikilink")，也不抑制[单胺氧化酶](../Page/单胺氧化酶.md "wikilink")。\[138\]同多数抗抑郁药类似，米氮平的[抗胆碱能](../Page/抗胆碱能.md "wikilink")、阻断[钠离子通道或阻断](../Page/鈉離子通道.md "wikilink")[钙离子通道的效应很弱甚至没有](../Page/钙通道.md "wikilink")。然而在过量食用时，米氮平具有更好的耐受性和低毒性。米氮平是TCA或[TeCA中最有效的H](../Page/四环类抗抑郁药.md "wikilink")<sub>1</sub>受体拮抗剂，拮抗H<sub>1</sub>受体是米氮平最强的活性，它在低剂量下为选择性H<sub>1</sub>受体拮抗剂。\[139\]\[140\]

米氮平的(S)-(+)对映体负责5-羟色胺5-HT<sub>2A</sub>和5-HT<sub>2C</sub>的拮抗作用，\[141\](R)-(-)对映体负责对5-HT<sub>3</sub>受体的拮抗作用。虽然(R)-(-)是很强的组胺H<sub>1</sub>受体的拮抗剂，两种对映体都参与了对组胺H<sub>1</sub>受体和肾上腺素α<sub>2</sub>受体的拮抗作用。

虽然没有临床意义，已经发现米氮平在高浓度的情况下是κ[阿片样受体的](../Page/阿片样肽受体.md "wikilink")[部分激动剂](../Page/部分激动剂.md "wikilink")\[142\]（EC<sub>50</sub>=7.2nm）。

#### α<sub>2</sub>肾上腺素受体

作为肾上腺素α<sub>2</sub>受体的拮抗剂，其功能主要是由于抑制自受体和异受体，提高去甲肾上腺素和5-羟色胺能的神经传递，特别是中央
5-HT<sub>1A</sub>受体介导的中缝背核和[海马的](../Page/海马体.md "wikilink")[神经递质的传导](../Page/神经递质.md "wikilink")；因此，米氮平的分类为NaSSA。间接地增强α<sub>1</sub>受体介导的5-羟色胺细胞放电和抑制、直接阻断5-羟色胺神经元上的异受体会增加细胞外5-羟色胺的浓度。\[143\]\[144\]\[145\]\[146\]\[147\]因此，米氮平被认为是5-HT<sub>1A</sub>受体的“间接[激动剂](../Page/激动剂.md "wikilink")
”。\[148\]中枢5-HT<sub>1A</sub>受体的活动增加被认为是大多数抗抑郁药物功效的主要原理。\[149\]

#### [5-HT<sub>2</sub>和](../Page/5-HT2受體.md "wikilink")5-HT<sub>3</sub>受体

对5-HT<sub>2</sub>受体亚族的拮抗作用和对5-HT<sub>2C</sub>受体的反向激动作用似乎是米氮平治疗抑郁的机理之一。\[150\]\[151\]米氮平能增加[前额叶皮质中的多巴胺能](../Page/前額葉皮質.md "wikilink")，对大鼠的研究结果表明，阻断α<sub>2</sub>受体和5-HT<sub>2C</sub>受体能对大鼠的此区域对多巴胺的释放去抑制。\[152\]米氮平对5-HT<sub>2A</sub>受体的拮抗作用对焦虑、失眠和[性功能有改进](../Page/性功能.md "wikilink")。\[153\]已证明米氮平可以降低人类和各种动物的寻药行为。它也正在被研究对[物质滥用的行为](../Page/物質濫用.md "wikilink")，以减少戒断效应和提高缓解率。\[154\]\[155\]\[156\]\[157\]

由于对5-HT<sub>3</sub>受体的拮抗作用，米氮平与批准的止吐药[昂丹司琼有着共同的作用](../Page/昂丹司琼.md "wikilink")，它可显著改善病人的恶心、呕吐、[腹泻和](../Page/腹瀉.md "wikilink")[肠易激综合征的症状](../Page/肠易激综合征.md "wikilink")。\[158\]米氮平可作为一种廉价的止吐药以替代昂丹司琼。\[159\]在一些研究中，在一些研究中，也发现米氮平对5-HT<sub>3</sub>受体的阻断可以改善焦虑并有效治疗[物质依赖](../Page/物質依賴.md "wikilink")。与物质滥用咨询相结合，米氮平成功地减少了对冰毒依赖的个体对冰毒的使用。\[160\]\[161\]\[162\]\[163\]与米氮平相比，SSRIs，[SNRIs](../Page/SNRIs.md "wikilink")，MAOIs和一些TCAs增加了5-HT<sub>2A</sub>，5-HT<sub>2C</sub>和5-HT<sub>3</sub>受体的一般活性，造成负面结果和副作用，其中最突出的包括[厌食](../Page/厌食.md "wikilink")、失眠和[性功能障碍](../Page/性功能障碍.md "wikilink")（丧失主动的[性欲](../Page/性欲.md "wikilink")、[性快感缺失](../Page/性快感.md "wikilink")）以及恶心和腹泻等等。因此，它通常与这些药物结合使用，以减少其副作用，并产生更强的抗抑郁作用。\[164\]\[165\]

米氮平不具有5-羟色胺能活性，不会引起5-羟色胺能副作用或[5-羟色胺综合征](../Page/血清素综合症.md "wikilink")。\[166\]\[167\]这与其不是5-羟色胺[再摄取抑制剂或MAOI](../Page/再攝取抑制劑.md "wikilink")，也不是5-羟色胺受体激动剂的事实一致。\[168\]\[169\]没有关于单独使用米氮平的5-羟色胺综合征的报道，并且未发现米氮平过量引起5-羟色胺综合征。\[170\]\[171\]\[172\]但是，有一些案例报告米氮平与SSRIs等5-羟色胺能药物联合应用引起5-羟色胺综合征，尽管这些报道非常罕见，并不一定暗示米氮平是致病因素。\[173\]\[174\]\[175\]\[176\]\[177\]\[178\]在MAOI中加入米氮平不会引起5-羟色胺综合征，并被认为是一种安全的组合。\[179\]\[180\]此外，米氮平实际上可用于治疗5-羟色胺综合征，至少有一篇文章发现它可有效地解决该综合征。\[181\]\[182\]\[183\]这是按照5-HT<sub>2A</sub>受体是导致5-羟色胺综合征的主要受体（而5-HT<sub>1A</sub>受体似乎是保护性的）。\[184\]\[185\]米氮平是一种有效的5-HT<sub>2A</sub>受体拮抗剂，而赛庚啶是一种具有这种特性的药物，可介导5-羟色胺综合征的恢复，并且在临床上已成熟，可作为对抗它的解毒剂。\[186\]\[187\]

#### H<sub>1</sub>受体

米氮平是一种非常强的H<sub>1</sub>受体反向激动剂，因此，它可以引起强大的镇静和催眠作用。\[188\]米氮平于健康志愿者的单15毫克剂量已被发现导致在H<sub>1</sub>受体的80％以上的占用并诱导强烈的嗜睡。\[189\]但是，经过长时间的慢性治疗，H<sub>1</sub>会脱敏，并且抗组胺能的效应变得更耐受。许多患者也可能在晚上服用以避免这种影响，这似乎是对抗它们的有效策略。阻断H<sub>1</sub>受体可以改善先前存在的患病个体的[过敏](../Page/过敏.md "wikilink")、[瘙痒](../Page/瘙痒症.md "wikilink")、恶心和失眠。然而，它也可能有助于增加体重。与H<sub>1</sub>受体相反，米氮平仅对[毒蕈碱乙酰胆碱受体仅具有低亲和力](../Page/蕈毒鹼型乙醯膽鹼受體.md "wikilink")，尽管在临床实践中有时仍会出现口干、[便秘和](../Page/便秘.md "wikilink")[瞳孔散大等](../Page/瞳孔散大.md "wikilink")[抗胆碱能副作用](../Page/抗胆碱能.md "wikilink")。\[190\]

### 药代动力学

米氮平的口服[生物利用度约为](../Page/生物利用度.md "wikilink")50％。有85%结合到[血浆蛋白](../Page/血浆蛋白.md "wikilink")。它主要在[肝脏中通过](../Page/肝脏.md "wikilink")[去甲基化和](../Page/去甲基化.md "wikilink")[细胞色素P450酶的](../Page/细胞色素P450.md "wikilink")[羟基化代谢](../Page/羟基化.md "wikilink")，其主要代谢物之一是去甲基米氮平。整体[清除半衰期为](../Page/消除半衰期.md "wikilink")20\~40小时。约15％由粪便、75％由尿液排出。\[191\]

## 社会文化

### 通用名

Mirtazapine是该药物的[英文](../Page/英文.md "wikilink")、[法文以及](../Page/法语.md "wikilink")[INN](../Page/国际非专利药品名称.md "wikilink")、USAN、[USP](../Page/美国药典.md "wikilink")、BAN、DCF、[JAN的](../Page/欧洲商品编码.md "wikilink")[通用名](../Page/通用名药物.md "wikilink")。\[192\]\[193\]它的[西班牙语通用名是mirtazapina](../Page/西班牙语.md "wikilink")、[德语通用名是Mirtazapin](../Page/德语.md "wikilink")、[拉丁语通用名是mirtazapinm](../Page/拉丁语.md "wikilink")。\[194\]

### 品牌名称

米氮平在全球使用相当多的商品名被出售，包括：

Adco-Mirteron、Afloyan、Amirel、Arintapin
Smelt、Avanza、Azapin、Beron、Bilanz、Calixta、Ciblex、Combar、Comenter、Depreram、Divaril、Esprital、Maz、Menelat、Mepirzapine、Merdaten、Meronin、Mi
Er
Ning、Milivin、Minelza、Minivane、Mirastad、Mirazep、Miro、Miron、Mirrador、Mirt、Mirta、Mirtabene、Mirtadepi、Mirtagamma、Mirtagen、Mirtalan、Mirtamor、Mirtamylan、Mirtan、Mirtaneo、Mirtapax、Mirtapil、Mirtapine、Mirtaron、Mirtastad、Mirtax、Mirtaz、Mirtazap、Mirtazapin、Mirtazapina、Mirtazapine、Mirtazapinum、Mirtazelon、Mirtazon、Mirtazonal、Mirtel、Mirtimash、Mirtin、Mirtine、Mirzapine、Mirzaten、Mirzest、Mitaprex、Mitaxind、Mitocent、Mitrazin、Mizapin、Motofen、Mytra、Norset、Noxibel、Pharmataz、Promyrtil、Rapizapine、Ramure、Redepra、Reflex、Remergil、Remergon、Remeron、Remirta、Rexer、Saxib、Sinmaron、Smilon、Tazepin、Tazimed、Tetrazic、Tifona、U-Mirtaron、U-zepine、Valdren、Vastat、Velorin、Yarocen、Zania、Zapex、Zestat、Zismirt、Zispin、Zuleptan、
Zulin.

### 历史

米氮平在1989年的时候由[Organon合成出来并被公布](../Page/欧加农国际.md "wikilink")。首次被批准用于治疗重性抑郁障碍是在1994年的荷兰。1996年，商品名为Remeron的米氮平被引入美国。\[195\]\[196\]

## 引用

[Category:止吐劑](https://zh.wikipedia.org/wiki/Category:止吐劑 "wikilink")
[Category:H1受体拮抗剂](https://zh.wikipedia.org/wiki/Category:H1受体拮抗剂 "wikilink")
[Category:血清素拮抗剂](https://zh.wikipedia.org/wiki/Category:血清素拮抗剂 "wikilink")
[Category:四环抗抑郁药](https://zh.wikipedia.org/wiki/Category:四环抗抑郁药 "wikilink")

1.

2.

3.
4.
5.

6.

7.
8.

9.

10.

11.
12.

13.
14.

15.

16.
17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.
28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43. [Pharmacological Interventions: 10.14. Clinical Practice
    Recommendations](https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s159).
    National Collaborating Centre for Mental Health/British
    Psychological Society. 2010.

44. [*Pharmacological Interventions: Third-Generation
    Antidepressants: 10.8.3.
    Mirtazapine*.](https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s68)
    National Collaborating Centre for Mental Health/British
    Psychological Society. 2010.

45. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R,
    Furukawa TA (December 2011). ["Mirtazapine versus other
    antidepressive agents for
    depression"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158430).
    *The Cochrane Database of Systematic Reviews* (12): CD006528.
    <doi:10.1002/14651858.CD006528.pub2>. PMC 4158430. PMID 22161405.

46. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa
    Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N,
    Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR
    (April 2018). ["Comparative efficacy and acceptability of 21
    antidepressant drugs for the acute treatment of adults with major
    depressive disorder: a systematic review and network
    meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889788).
    *Lancet*. **391** (10128): 1357–1366.
    <doi:10.1016/S0140-6736(17)32802-7>. PMC 5889788. PMID 29477251.

47. Thompson C (June 2002). ["Onset of action of antidepressants:
    results of different analyses"](https://dx.doi.org/10.1002/hup.386).
    *Human Psychopharmacology*. 17 Suppl 1: S27–32.
    <doi:10.1002/hup.386>. PMID 12404667.

48. Taylor D, Paton C, Shitij K (2012). *Maudsley Prescribing Guidelines
    in Psychiatry* (11th ed.). West Sussex: Wiley-Blackwell. ISBN
    978-0-47-097948-8.

49. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R,
    Furukawa TA (December 2011). ["Mirtazapine versus other
    antidepressive agents for
    depression"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158430).
    *The Cochrane Database of Systematic Reviews* (12): CD006528.
    <doi:10.1002/14651858.CD006528.pub2>. PMC 4158430. PMID 22161405.

50. Anttila SA, Leinonen EV (2001). "A review of the pharmacological and
    clinical profile of mirtazapine". *CNS Drug Rev*. **7** (3): 249–64.
    <doi:10.1111/j.1527-3458.2001.tb00198.x>. PMID 11607047.

51. Fawcett J, Barkin RL (December 1998). "Review of the results from
    clinical studies on the efficacy, safety and tolerability of
    mirtazapine for the treatment of patients with major depression".
    *Journal of Affective Disorders*. **51** (3): 267–85.
    <doi:10.1016/S0165-0327(98)00224-9>. PMID 10333982.

52. Möller HJ (December 2006). "Is there evidence for negative effects
    of antidepressants on suicidality in depressive patients? A
    systematic review". *European Archives of Psychiatry and Clinical
    Neuroscience*. **256** (8): 476–96. <doi:10.1007/s00406-006-0689-8>.
    PMID 17143567.

53. Abo-Zena RA, Bobek MB, Dweik RA (April 2000). "Hypertensive urgency
    induced by an interaction of mirtazapine and clonidine".
    *Pharmacotherapy*. **20** (4): 476–8.
    <doi:10.1592/phco.20.5.476.35061>. PMID 10772378.

54. 《米氮平片说明书》，山德士（中国）制药有限公司。

55.
56. Benazzi F (June 1998). "Mirtazapine withdrawal symptoms". Canadian
    Journal of Psychiatry. Revue canadienne de psychiatrie. 43 (5): 525.
    PMID
    9653542.[<sup>\[不可靠的醫學來源?\]</sup>](https://zh.wikipedia.org/wiki/wikipedia:可靠來源_\(醫學\) "wikilink")

57. Blier P (2001). "Pharmacology of rapid-onset antidepressant
    treatment strategies". *The Journal of Clinical Psychiatry*. 62
    Suppl 15: 12–7. PMID 11444761.

58. Vlaminck JJ, van Vliet IM, Zitman FG (March 2005). "\[Withdrawal
    symptoms of antidepressants\]". *Nederlands Tijdschrift Voor
    Geneeskunde* (in Dutch and Flemish). **149** (13): 698–701. PMID
    15819135.

59.
60. <sup>Berigan TR (June 2001). "Mirtazapine-Associated Withdrawal
    Symptoms: A Case Report". Primary Care Companion to the Journal of
    Clinical Psychiatry. 3 (3): 143. <doi:10.4088/PCC.v03n0307a>. PMC
    181176. PMID
    15014614.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/wikipedia:可靠來源_\(醫學\) "wikilink")\]</sup>

61. <sup>Klesmer J, Sarcevic A, Fomari V (August 2000). "Panic attacks
    during discontinuation of mirtazepine". Canadian Journal of
    Psychiatry. Revue canadienne de psychiatrie. 45 (6): 570–1. PMID
    10986577.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/wikipedia:可靠來源_\(醫學\) "wikilink")\]</sup>

62. MacCall C, Callender J (October 1999). "Mirtazapine withdrawal
    causing hypomania". The British Journal of Psychiatry. 175 (4): 390.
    <doi:10.1192/bjp.175.4.390a>. PMID
    10789310.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/wikipedia:可靠來源_\(醫學\) "wikilink")\]

63. Ali S, Milev R (May 2003). "Switch to mania upon discontinuation of
    antidepressants in patients with mood disorders: a review of the
    literature". *Canadian Journal of Psychiatry. Revue canadienne de
    psychiatrie*. **48** (4): 258–64. <doi:10.1177/070674370304800410>.
    PMID 12776393.

64. Timmer CJ, Sitsen JM, Delbressine LP (June 2000). "Clinical
    pharmacokinetics of mirtazapine". Clinical Pharmacokinetics. 38 (6):
    461–74. <doi:10.2165/00003088-200038060-00001>. PMID 10885584.

65. Anttila SA, Leinonen EV (2001). "A review of the pharmacological and
    clinical profile of mirtazapine". *CNS Drug Rev*. **7** (3): 249–64.
    <doi:10.1111/j.1527-3458.2001.tb00198.x>. PMID 11607047.

66.
67.
68. ["Mirtazapine Monograph for Professionals -
    Drugs.com".](https://www.drugs.com/monograph/mirtazapine.html)

69. Fawcett J, Barkin RL (December 1998). "Review of the results from
    clinical studies on the efficacy, safety and tolerability of
    mirtazapine for the treatment of patients with major depression".
    *Journal of Affective Disorders*. **51** (3): 267–85.
    <doi:10.1016/S0165-0327(98)00224-9>. PMID 10333982.

70. Stahl SM (2008). [Stahl's Essential Psychopharmacology Online: Print
    and
    Online.](http://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c57_p325-330.html.therapeutics&name=Mirtazapine&title=Therapeutics)
    Cambridge, UK: Cambridge University Press. ISBN 0-521-74609-4.

71. Silva J, Mota J, Azevedo P (March 2016). "California rocket fuel:
    And what about being a first line treatment?". *European
    Psychiatry*. **33**: S551. <doi:10.1016/j.eurpsy.2016.01.2033>.

72. Taylor D, Paton C, Shitij K (2012). *Maudsley Prescribing Guidelines
    in Psychiatry* (11th ed.). West Sussex: Wiley-Blackwell. ISBN
    978-0-47-097948-8.

73. White N, Litovitz T, Clancy C (December 2008). ["Suicidal
    antidepressant overdoses: a comparative analysis by antidepressant
    type"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550116/pdf/13181_2009_Article_BF03161207.pdf)
    (PDF). *Journal of Medical Toxicology*. **4** (4): 238–50.
    <doi:10.1007/bf03161207>. PMC 3550116. PMID 19031375.

74. Fawcett J, Barkin RL (December 1998). "Review of the results from
    clinical studies on the efficacy, safety and tolerability of
    mirtazapine for the treatment of patients with major depression".
    Journal of Affective Disorders. 51 (3): 267–85.
    <doi:10.1016/S0165-0327(98)00224-9>. PMID 10333982.

75. <sup>Holzbach R, Jahn H, Pajonk FG, Mähne C (November 1998).
    "Suicide attempts with mirtazapine overdose without complications".
    Biological Psychiatry. 44 (9): 925–6.
    <doi:10.1016/S0006-3223(98)00081-X>. PMID
    9807651.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/Wikipedia:可靠來源_\(醫學\) "wikilink")\]</sup>

76. Retz W, Maier S, Maris F, Rösler M (November 1998). "Non-fatal
    mirtazapine overdose". International Clinical Psychopharmacology. 13
    (6): 277–9. <doi:10.1097/00004850-199811000-00007>. PMID
    9861579.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/Wikipedia:可靠來源_\(醫學\) "wikilink")\]

77. Nikolaou P, Dona A, Papoutsis I, Spiliopoulou C, Maravelias C.
    "Death Due to Mirtazapine Overdose". in "Abstracts of the XXIX
    International Congress of the European Association of Poison Centres
    and Clinical Toxicologists, May 12–15, 2009, Stockholm, Sweden".
    Clinical Toxicology. 47 (5): 436–510. 2009.
    <doi:10.1080/15563650902952273>.

78. Baselt, RC (2008). *Disposition of Toxic Drugs and Chemicals in Man*
    (8th ed.). Foster City, CA: Biomedical Publications. pp. 1045–7.
    ISBN 978-0-9626523-7-0.

79. <sup>Buckley NA, McManus PR (December 2002). ["Fatal toxicity of
    serotoninergic and other antidepressant drugs: analysis of United
    Kingdom mortality
    data"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137809). BMJ.
    325 (7376): 1332–3. <doi:10.1136/bmj.325.7376.1332>. PMC 137809.
    PMID
    12468481.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/Wikipedia:可靠來源_\(醫學\) "wikilink")\]</sup>

80. Roth, BL; Driscol, J. ["PDSP K<sub>i</sub>
    Database"](https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=mirtazepine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query).
    *Psychoactive Drug Screening Program (PDSP)*. University of North
    Carolina at Chapel Hill and the United States National Institute of
    Mental Health. Retrieved 14 August 2017.

81. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997).
    "Pharmacological profile of antidepressants and related compounds at
    human monoamine transporters". *Eur. J. Pharmacol*. **340**(2–3):
    249–58. <doi:10.1016/s0014-2999(97)01393-9>. PMID 9537821.

82. Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE,
    Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE
    (2006). "Synthesis and biodistribution of \[11C\]R107474, a new
    radiolabeled alpha2-adrenoceptor antagonist". *Bioorg. Med. Chem*.
    **14** (13): 4526–34. <doi:10.1016/j.bmc.2006.02.029>. PMID
    16517171.

83. Gillman PK (2007). ["Tricyclic antidepressant pharmacology and
    therapeutic drug interactions
    updated"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014120).
    *Br. J. Pharmacol*. **151** (6): 737–48.
    <doi:10.1038/sj.bjp.0707253>. PMC 2014120. PMID 17471183.

84.
85. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997).
    "Pharmacological profile of antidepressants and related compounds at
    human monoamine transporters". *Eur. J. Pharmacol*. **340**(2–3):
    249–58. <doi:10.1016/s0014-2999(97)01393-9>. PMID 9537821.

86. Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE,
    Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE
    (2006). "Synthesis and biodistribution of \[11C\]R107474, a new
    radiolabeled alpha2-adrenoceptor antagonist". *Bioorg. Med. Chem*.
    **14** (13): 4526–34. <doi:10.1016/j.bmc.2006.02.029>. PMID
    16517171.

87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97. Fernández J, Alonso JM, Andrés JI, Cid JM, Díaz A, Iturrino L, Gil
    P, Megens A, Sipido VK, Trabanco AA (2005). "Discovery of new
    tetracyclic tetrahydrofuran derivatives as potential broad-spectrum
    psychotropic agents". *J. Med. Chem*. **48**(6): 1709–12.
    <doi:10.1021/jm049632c>. PMID 15771415.

98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123. Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (2012).
     "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R
     receptors with 34 antidepressants and antipsychotics". *Naunyn
     Schmiedebergs Arch. Pharmacol*. **385** (2): 145–70.
     <doi:10.1007/s00210-011-0704-0>. PMID 22033803.

124.
125. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM
     (April 1988). "Neurochemical and autonomic pharmacological profiles
     of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers".
     *Neuropharmacology*. **27**(4): 399–408.
     <doi:10.1016/0028-3908(88)90149-9>. PMID 3419539.

126.
127.
128.
129.
130.
131.
132.
133. Gillman PK (2006). "A systematic review of the serotonergic effects
     of mirtazapine in humans: implications for its dual action status".
     *Hum Psychopharmacol*. **21** (2): 117–25. <doi:10.1002/hup.750>.
     PMID 16342227.

134. Frazer A (1997). "Pharmacology of antidepressants". *J Clin
     Psychopharmacol*. 17 Suppl 1: 2S–18S.
     <doi:10.1097/00004714-199704001-00002>. PMID 9090573.

135.
136.
137.
138. Fisar Z, Hroudová J, Raboch J (2010). "Inhibition of monoamine
     oxidase activity by antidepressants and mood stabilizers". *Neuro
     Endocrinology Letters*. **31** (5): 645–56. PMID 21200377.

139.
140.
141.
142. Olianas MC, Dedoni S, Onali P (November 2012). "The atypical
     antidepressant mianserin exhibits agonist activity at κ-opioid
     receptors". *British Journal of Pharmacology*. **167** (6):
     1329–41. <doi:10.1111/j.1476-5381.2012.02078.x>. PMC 3504997.
     PMID 22708686.

143.
144.
145. <sup>De Boer T, Nefkens F, Van Helvoirt A (February 1994). "The
     alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin
     transmission in vivo". European Journal of Pharmacology. 253 (1–2):
     R5–6. <doi:10.1016/0014-2999(94)90778-1>. PMID
     7912194.[\[不可靠的醫學來源?](https://zh.wikipedia.org/wiki/Wikipedia:可靠來源_\(醫學\) "wikilink")\]</sup>

146. Berendsen HH, Broekkamp CL (October 1997). "Indirect in vivo
     5-HT1A-agonistic effects of the new antidepressant mirtazapine".
     Psychopharmacology. 133 (3): 275–82. <doi:10.1007/s002130050402>.
     PMID 9361334.

147. Nakayama K, Sakurai T, Katsu H (April 2004). "Mirtazapine increases
     dopamine release in prefrontal cortex by 5-HT1A receptor
     activation". Brain Research Bulletin. 63 (3): 237–41.
     <doi:10.1016/j.brainresbull.2004.02.007>. PMID
     15145142.[\[不可靠的医学来源?](https://zh.wikipedia.org/wiki/Wikipedia:可靠來源_\(醫學\) "wikilink")\]

148.
149. Blier P, Abbott FV (January 2001). "Putative mechanisms of action
     of antidepressant drugs in affective and anxiety disorders and
     pain" (PDF). Journal of Psychiatry & Neuroscience. 26 (1): 37–43.
     PMC 1408043. PMID 11212592.

150. Millan MJ (2005). "Serotonin 5-HT<sub>2C</sub> receptors as a
     target for the treatment of depressive and anxious states: focus on
     novel therapeutic strategies". *Thérapie*. **60** (5): 441–60.
     <doi:10.2515/therapie:2005065>. PMID 16433010.

151. Dekeyne A, Millan MJ (April 2009). "Discriminative stimulus
     properties of the atypical antidepressant, mirtazapine, in rats: a
     pharmacological characterization". Psychopharmacology. 203 (2):
     329–41. <doi:10.1007/s00213-008-1259-8>. PMID 18709360.

152. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D,
     Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (March 2000).
     "Mirtazapine enhances frontocortical dopaminergic and corticolimbic
     adrenergic, but not serotonergic, transmission by blockade of
     alpha2-adrenergic and serotonin2C receptors: a comparison with
     citalopram". The European Journal of Neuroscience. 12 (3): 1079–95.
     <doi:10.1046/j.1460-9568.2000.00982.x>. PMID 10762339.

153.
154. Graves SM, Napier TC (June 2012). "SB 206553, a putative
     5-HT<sub>2C</sub> inverse agonist, attenuates
     methamphetamine-seeking in rats". *BMC Neuroscience*. **13** (1):
     65. <doi:10.1186/1471-2202-13-65>. PMC 3441362. PMID 22697313.

155. Rose ME, Grant JE (2008). "Pharmacotherapy for methamphetamine
     dependence: a review of the pathophysiology of methamphetamine
     addiction and the theoretical basis and efficacy of
     pharmacotherapeutic interventions". *Annals of Clinical
     Psychiatry*. **20** (3): 145–55. <doi:10.1080/10401230802177656>.
     PMID 18633741.

156. Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for
     methamphetamine abuse: a literature review for the clinician".
     *Journal of Pharmacy Practice*. **24** (6): 541–50.
     <doi:10.1177/0897190011426557>. PMID 22095579.

157. Brensilver M, Heinzerling KG, Shoptaw S (September 2013).
     "Pharmacotherapy of amphetamine-type stimulant dependence: an
     update". *Drug and Alcohol Review*. **32** (5): 449–60.
     <doi:10.1111/dar.12048>. PMC 4251965. PMID 23617468.

158. Kast RE (September 2001). "Mirtazapine may be useful in treating
     nausea and insomnia of cancer chemotherapy". *Supportive Care in
     Cancer*. **9**(6): 469–70. <doi:10.1007/s005200000215>. PMID
     11585276.

159. Kast RE, Foley KF (July 2007). "Cancer chemotherapy and cachexia:
     mirtazapine and olanzapine are 5-HT<sub>3</sub> antagonists with
     good antinausea effects". *European Journal of Cancer Care*. **16**
     (4): 351–4. <doi:10.1111/j.1365-2354.2006.00760.x>. PMID 17587360.

160. Costall B, Naylor RJ, Tyers MB (1990). "The psychopharmacology of
     5-HT<sub>3</sub> receptors". *Pharmacology & Therapeutics*. **47**
     (2): 181–202. <doi:10.1016/0163-7258(90)90086-H>. PMID 2203069.

161.
162.
163.
164.
165. Caldis EV, Gair RD (October 2004). "Mirtazapine for treatment of
     nausea induced by selective serotonin reuptake inhibitors".
     *Canadian Journal of Psychiatry. Revue canadienne de psychiatrie*.
     **49** (10): 707. <doi:10.1177/070674370404901014>. PMID 15560319.

166. Gillman PK (June 2006). "A review of serotonin toxicity data:
     implications for the mechanisms of antidepressant drug action".
     *Biological Psychiatry*. **59** (11): 1046–51.
     <doi:10.1016/j.biopsych.2005.11.016>. PMID 16460699.

167.
168.
169.
170.
171.
172. Berling I, Isbister GK (2014). "Mirtazapine overdose is unlikely to
     cause major toxicity". Clin Toxicol. 52 (1): 20–4.
     <doi:10.3109/15563650.2013.859264>. PMC 3894718. PMID 24228948.

173.
174. Freijo Guerrero J, Tardón Ruiz de Gauna L, Gómez JJ, Aguilera
     Celorrio L (2009). "\[Serotonin syndrome after administration of
     mirtazapine in a critical care unit\]". Rev Esp Anestesiol Reanim
     (in Spanish; Castilian). 56 (8): 515–6. PMID 19994622.

175. Butler MC, Di Battista M, Warden M (2010). "Sertraline-induced
     serotonin syndrome followed by mirtazapine reaction". *Prog.
     Neuropsychopharmacol. Biol. Psychiatry*. **34** (6): 1128–9.
     <doi:10.1016/j.pnpbp.2010.04.015>. PMID 20430060.

176. Decoutere L, De Winter S, Vander Weyden L, Spriet I, Schrooten M,
     Tournoy J, Fagard K (2012). "A venlafaxine and mirtazapine-induced
     serotonin syndrome confirmed by de- and re-challenge". *Int J Clin
     Pharm*. **34** (5): 686–8. <doi:10.1007/s11096-012-9666-7>. PMID
     22752315.

177. Ansermot N, Hodel PF, Eap CB (2014). "Serotonin toxicity after
     addition of mirtazapine to escitalopram". *J Clin Psychopharmacol*.
     **34** (4): 540–1. <doi:10.1097/JCP.0000000000000170>. PMID
     24977717.

178. Wu CS, Tong SH, Ong CT, Sung SF (2015). "Serotonin Syndrome Induced
     by Combined Use of Mirtazapine and Olanzapine Complicated with
     Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A
     Case Report". *Acta Neurol Taiwan*. **24** (4): 117–21. PMID
     27333965.

179.
180.
181.
182. Hoes MJ, Zeijpveld JH (1996). "Mirtazapine as treatment for
     serotonin syndrome". *Pharmacopsychiatry*. **29** (2): 81.
     <doi:10.1055/s-2007-979550>. PMID 8741027.

183. Shioda K, Nisijima K, Yoshino T, Kato S (2010). "Mirtazapine
     abolishes hyperthermia in an animal model of serotonin syndrome".
     Neurosci. Lett. 482 (3): 216–9. <doi:10.1016/j.neulet.2010.07.039>.
     PMID 20655983.

184.
185.
186.
187. qbal MM, Basil MJ, Kaplan J, Iqbal MT (2012). "Overview of
     serotonin syndrome". *Ann Clin Psychiatry*. **24** (4): 310–8. PMID
     23145389.

188.
189. Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R,
     Matsuoka H, Yanai K (2013). "Histamine H₁ receptor occupancy by the
     new-generation antidepressants fluvoxamine and mirtazapine: a
     positron emission tomography study in healthy volunteers".
     *Psychopharmacology*. **230**(2): 227–34.
     <doi:10.1007/s00213-013-3146-1>. PMID 23728612.

190. Burrows GD, Kremer CM (April 1997). "Mirtazapine: clinical
     advantages in the treatment of depression". Journal of Clinical
     Psychopharmacology. 17 Suppl 1: 34S–39S.
     <doi:10.1097/00004714-199704001-00005>. PMID 9090576.

191. Schatzberg, Alan F. (2009). "Chapter 21: Mirtazapine". In
     Schatzberg, Alan F.; Nemeroff, Charles B. *The American Psychiatric
     Publishing Textbook of Psychopharmacology* (4th ed.). Washington,
     D.C.: American Psychiatric Pub. ISBN 9781585623099.

192. *Index Nominum 2000: International Drug Directory*. Taylor &
     Francis. 2000. pp. 696–. ISBN 978-3-88763-075-1.

193. I.K. Morton; Judith M. Hall (6 December 2012). *Concise Dictionary
     of Pharmacological Agents: Properties and Synonyms*. Springer
     Science & Business Media. p. 183. ISBN 978-94-011-4439-1.

194.
195.
196. Kaspersen, Frans M.; Van Rooij, Fons A. M.; Sperling, Eric G. M.;
     Wieringa, Joop H. (September 1989). "The synthesis of org 3770
     labelled with 3H, 13C AND 14C". *Journal of Labelled Compounds and
     Radiopharmaceuticals*. **27** (9): 1055–1068.
     <doi:10.1002/jlcr.2580270911>.